0000950170-24-069401.txt : 20240605 0000950170-24-069401.hdr.sgml : 20240605 20240605165319 ACCESSION NUMBER: 0000950170-24-069401 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240603 FILED AS OF DATE: 20240605 DATE AS OF CHANGE: 20240605 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Scott Randal W. CENTRAL INDEX KEY: 0001337801 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38959 FILM NUMBER: 241022724 MAIL ADDRESS: STREET 1: 171 MAIN STREET #225 CITY: LOS ALTOS STATE: CA ZIP: 94022 FORMER NAME: FORMER CONFORMED NAME: Scott Randal W DATE OF NAME CHANGE: 20050901 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc. CENTRAL INDEX KEY: 0001743881 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3160 PORTER DR. STREET 2: SUITE 250 CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 3160 PORTER DR. STREET 2: SUITE 250 CITY: PALO ALTO STATE: CA ZIP: 94304 FORMER COMPANY: FORMER CONFORMED NAME: BridgeBio Pharma LLC DATE OF NAME CHANGE: 20180618 4 1 ownership.xml 4 X0508 4 2024-06-03 0001743881 BridgeBio Pharma, Inc. BBIO 0001337801 Scott Randal W. C/O BRIDGEBIO PHARMA, INC. 3160 PORTER DR., SUITE 250 PALO ALTO CA 94304 true false false false true Common Stock 2024-06-03 4 S false 800 28.6844 D 5700 I By Thinking Bench Capital LLC Common Stock 2024-06-03 4 S false 200 29.475 D 5500 I By Thinking Bench Capital LLC Common Stock 2024-06-04 4 S false 1500 31.30 D 4000 I By Thinking Bench Capital LLC Common Stock 5000 D This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by Thinking Bench Capital LLC on June 6, 2023. Represents the weighted average sale price of the shares sold ranging from $28.31 to $29.24 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold ranging from $29.44 to $29.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. /s/ Brian C. Stephenson, Attorney-in-Fact 2024-06-05